| 表没食子儿茶素没食子酸酯相关肿瘤临床试验研究进展 |
| |
| 引用本文： | 雷梦侠,王丹丹,于飞,靳小迎,陈雪松. 表没食子儿茶素没食子酸酯相关肿瘤临床试验研究进展[J]. 中国肿瘤临床, 2018, 45(2): 97-102. DOI: 10.3969/j.issn.1000-8179.2018.02.523 |
| |
| 作者姓名： | 雷梦侠 王丹丹 于飞 靳小迎 陈雪松 |
| |
| 作者单位： | 哈尔滨医科大学附属肿瘤医院内科（哈尔滨市150000） |
| |
| 基金项目： | 国家自然科学基金项目81573001 |
| |
| 摘 要： | 表没食子儿茶素没食子酸酯[（-）epigallo-catechingallate，EGCG]作为绿茶最主要的茶多酚，也是最主要的抗肿瘤活性成分，在肿瘤防治方面被广泛研究。在细胞和动物水平上已经证实其具有诱导肿瘤细胞凋亡、抑制侵袭转移、抑制血管生成等多种抗癌作用。现EGCG在肿瘤临床试验阶段，已经陆续出现相关的临床研究成果。本文通过整理近年来EGCG的全球肿瘤临床试验及相关成果，对其在临床试验中的安全性、防治效果以及所面临的挑战等方面的研究进展进行系统综述。
|
| 关 键 词： | EGCG 肿瘤 临床试验 安全性 |
| 收稿时间： | 2017-05-09 |
Research advances of (-) epigallo-catechingallate in cancer clinical trials |
| |
| Affiliation: | Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150000, China |
| |
| Abstract: | Epigallo-catechingallate (EGCG), the most abundant polyphenol and important active ingredient in green tea, is widely studied in cancer prevention and treatment. It has demonstrated various anti-cancer activities in vitro and in vivo, including induction of apoptosis, as well as inhibition of tumor cell invasion, migration, and angiogenesis. EGCG has been in the clinical stage of drug development with some findings currently available. In the present review, we systematically summarize the research advances of EGCG in cancer treatment through collection of global clinical trials and related results and discuss its safety, research efficacy, and critical challenges. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
